progression. This retrospective study, therefore, investigated expression of the LIMK1 gene in primary ovarian tumour tissue samples and evaluated the correlation between LIMK1 gene expression and progression of ovarian carcinoma. METHODS: LIMK1 protein levels were detected by immunohistochemistry in ovarian tissue samples from 57 patients with primary ovarian epithelial tumours (benign, n = 13; borderline, n = 14; carcinoma, n = 30) and 10 patients with normal ovaries. LIMK1 protein levels were evaluated by calculating the product of the scores for stain intensity and percentage of cells stained. RESULTS: There was a significant correlation between increasing LIMK1 protein levels and increasing disease severity, from normal ovarian tissues through benign and borderline tumours to ovarian carcinoma. There was also a significant correlation between increasing LIMK1 protein levels and increasingly poor levels of differentiation of ovarian carcinoma. CONCLUSIONS: LIMK1 is associated with the development of ovarian cancer and with the level of tumour differentiation in patients with ovarian carcinoma.
Introduction
Primary ovarian carcinoma is the leading cause of death in women with gynaecologically related cancers and most cases of ovarian carcinoma are diagnosed at an advanced disease stage. 1, 2 In Korea, the age-standardized incidence rates between 1993 and 2002 were 3.79 and 4.74 per 100 000 women, respectively, and the incidence rate was observed to increase with increasing age. 3 The 5-year overall survival rates for patients with advanced ovarian cancer undergoing comprehensive surgical procedures have been estimated at approximately 31 -47%. 4, 5 Studies focused on improving early diagnosis 6, 7 or using cytoreductive surgery 8 and chemo therapeutic agents 9 have shown that, in most cases, ovarian tumours W Zhang, N Gan, J Zhou LIMK1 and ovarian carcinoma development and differentiation eventually spread throughout the peritoneal cavity. This phenomenon suggests that the development of ovarian carcinoma is affected by factors that induce the spread of tumour cells from primary to distal sites. 10 -12 The LIM kinases (LIMK), including LIMK1 and LIMK2, are serine protein kinases involved in the regulation of actin polymerization and microtubule disassembly, via phosphorylation and inactivation of the actin-binding proteins, actin depolymerizing factor and cofilin. 13 LIMK1 acts as a network hub for signalling pathways that link rho-guanosine triphosphate hydrolase (rho-GTPase) proteins with regulation of the actin cytoskeleton; 14 in addition, the amoeboid mode of tumour cell invasion (mediated by upregulation of signalling involving rhoand rho-associated coiled-coil containing protein kinase [rho/ROCK signalling]), is dependent on the increased capacity of metastatic cells to generate force. 15 The phosphorylation of cofilin by LIMK1 results in the stabilization of cofilin, and activated LIMK1 contributes to the formation of key actin structures such as membrane protrusions, stress fibres and the contractile ring that forms during cytokinesis. 16 In functional studies, increased expression of LIMK1 in human breast cancer cell lines has been shown to result in increased cellular invasion. 17 Suppression of LIMK1 in the same cell lines resulted in suppression of Matrigel™ (BD Biosciences, San Jose, CA, USA) invasion in vitro, and inhibition of liver, lung and bone metastases in vivo. 17 The inhibition of LIMK1, by processes such as RNA-interference-mediated knockdown or pharmacological inhibition, may provide a means of blocking LIMK1-mediated cellular invasion. 18 Although LIMK1 appears to play a role in the development of breast cancer, the precise role of LIMK1 expression in the progression of ovarian carcinoma remains unconfirmed.
We put forward the hypothesis that increased LIMK1 expression may result in increased disease progression in ovarian cancer. Using immunohistochemistry, the present study compared levels of LIMK1 protein in ovarian tissue samples from patients with primary epithelial tumours, epithelial borderline tumours or benign tumours, together with normal ovarian tissue samples from patients with hysteromyoma, and explored the relationship between LIMK1 gene expression and ovarian carcinoma progression.
Patients and methods

STUDY POPULATION
All tissue samples used in this retrospective observational study were obtained from consecutive patients treated at the Women's Hospital, affiliated to the School of Medicine, Zhejiang University, Hangzhou, China between June 1998 and July 2006. All samples were submitted to the Division of Pathology at the Women's Hospital for routine analysis, and all cases were reviewed independently by at least two pathologists at the Women's Hospital, according to the pathological criteria of the World Health Organization. 19 Patients who underwent chemotherapy prior to surgery were excluded from the study. Normal ovarian tissue samples, collected from patients > 50 years of age who underwent surgery for hysteromyoma at the Women's Hospital, were also studied.
The use of these samples was approved by the Institutional Review Board of the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China (No. 201104120). Written or verbal consent was obtained from each patient or from their next of kin.
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HISTOLOGY AND IMMUNOHISTOCHEMISTRY
Specimens
were preserved in 4% paraformaldehyde for 24 h. Histological staining and immunohistochemistry were performed on 8-µm sections of routinely prepared paraffin-embedded tissues. Sections were deparaffinized and rehydrated using routine methods. Sections for histological analysis were stained with 0.3% cresyl violet (VWR International, Buffalo Grove, IL, USA).
Sections for immunohistochemical analysis were treated for antigen retrieval with 10. Immunolabelling was visualized with 0.05% diamino benzidine plus 0.3% hydrogen peroxide in 0.01 M PBS (pH 7.4). Sections were counterstained with haematoxylin and eosin, then dehydrated through ethanol and xylene before coverslips were applied. Rat IgG (1:200 dilution; Biomeda, Foster City, CA, USA) was used instead of primary antibody, as a negative control.
Staining scores for LIMK1 were determined at × 400 magnification using UTHSCSA ImageTool version 3.0 (University of Texas Health Science Center at San Antonio, San Antonio, TX, USA). Relative levels of LIMK1 protein were determined as the product of immunostaining intensity and percentage of cells stained. Both items were scored on 0 -3-point scales (maximal scores of 9 [i.e. 3 × 3]; minimal scores of 0). 20 Immunostaining intensity was scored as: 0, no staining; 1, light staining; 2, moderate staining; 3, heavy staining. Percentage of cells stained was scored as: 0, no detectable staining; 1, 1 -33% of cells stained; 2, 34 -66% of cells stained; 3, 67 -100% of cells stained.
STATISTICAL ANALYSES
All data were presented as mean ± SD. Statistical analyses were performed using SPSS ® statistical software, version 14.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Between-group differences were compared using the Kruskal-Wallis test. Correlations between overall LIMK staining scores and tumour groups were assessed using Pearson's correlation coefficient. A P-value < 0.05 was considered to be statistically significant.
Results
A total of 67 tissue samples were analysed: normal ovaries (n = 10); benign ovarian tumours (n = 13); borderline tumours (n = 14); ovarian carcinomas (n = 30; poorly differentiated in seven cases, moderately differentiated in 13 cases, well differentiated in 10 cases).
Diffuse cytoplasmic staining for LIMK1 was observed, with the percentage of cells stained and the intensity of staining varying among the different tumour types (Fig. 1 ).
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Results of the overall staining scores for LIMK1 were: normal ovarian tissue -seven samples scored 0 and three scored 1; benign ovarian tumours -three samples scored 0, four scored 1, four scored 2 and two scored 3; ovarian borderline tumours, three samples scored 2, four scored 3, three scored 4 and four scored 6; ovarian carcinomas -five samples scored 4, 15 scored 6 and 10 scored 9. There was a significant positive correlation between the overall mean staining score and disease severity, with mean scores increasing from normal ovarian tissues through benign and borderline tissues to ovarian carcinoma (r = 0.884, P < 0.01; Table 1 ).
In ovarian carcinoma samples only, the immunoreactivity of LIMK1 was associated with the degree of tumour differentiation (Fig. 2 ). Pearson's correlation coefficient indicated that LIMK1 protein levels were significantly correlated with grade of differentiation: patients with poorly differentiated ovarian carcinoma were more likely to be highly positive for LIMK1 than those with moderately or well differentiated disease (r = 0.550, P < 0.01; Table 1 ).
Discussion
Based on previous analyses of the molecular alterations underlying ovarian cancers, 21 we put forward the hypothesis that overexpression of LIMK1 in primary ovarian epithelial tumour tissue plays a role in Data presented as mean ± SD. Significant positive correlations were observed between overall mean staining score and tumour type (P < 0.05 [r = 0.884]) and between overall mean staining score and decreasing level of tumour differentiation (P < 0.01 [r = 0.550]); Pearson's correlation coefficient. a LIMK1 overall staining score was determined as the product of immunostain intensity and the percentage of cells stained. Items were scored on 0 -3-point scales, allowing maximal scores of 9 (i.e. 3 × 3) and minimal scores of 0. Immunostaining intensity was scored as: 0, no staining; 1, light staining; 2, moderate staining; 3, heavy staining. Percentage of cells stained was scored as: 0, no detectable staining; 1, 1 -33% of cells stained; 2, 34 -66% of cells stained; 3, 67 -100% of cells stained. ovarian carcinoma progression. The present study showed that diffuse cytoplasmic staining for LIMK1 occurred, with the percentage of cells stained and staining intensity varying between the different tumour types and normal ovarian tissue samples. For example, LIMK1 was present in only very few cells (and at low intensity) in normal ovarian tissue, whereas most ovarian carcinoma samples scored highly, with a large percentage of cells stained at high intensity. A significant correlation between increasing LIMK1 staining score and increasing disease severity was observed. Interestingly, the invasiveness of malignant cancer cells depends on altered regulation of cell migration. In turn, cell migration is the product of multistep processes initiated by the formation of membrane protrusions in response to migratory and chemotactic stimuli. 22 The driving force for membrane protrusion is W Zhang, N Gan, J Zhou LIMK1 and ovarian carcinoma development and differentiation localized polymerization of submembrane actin filaments. 22 Research has shown that the actin cytoskeleton and its regulatory proteins are dynamically remodelled and involved in cell migration. 22 Cofilin is specifically targeted to filopodia upon stalling of protrusion and during retraction, and electron tomography has established a precise correlation between filopodial actin filament and/or bundle fragmentation and cofilin accumulation. 23 Both LIMK1 and LIMK2 are involved in actin cytoskeletal regulation downstream of the rho-family of GTPases, p21-activated protein kinases and ROCK. 13 Activated LIMKs inhibit the actin depolymerization activity of cofilin by phosphorylation of cofilin. 18 Cancer cells are capable of invading other tissues, either as individual cells or as part of a collective invasion. 18 For collectively invading tumour cells, LIMK1 is required in the leading cells to ensure effective degradation of the extracellular matrix, to facilitate threedimensional invasion. 18 Research has demonstrated that LIMK1 is expressed in both cytoplasmic and nuclear compartments of cells in human breast cancer tissue, and contributes to mammary epithelial cell tumorigenesis. 17 In other research, suppression of LIMK1 and the rho/ROCK pathways has resulted in reduced B16BL6 melanoma cell migration, invasion, adhesion and metastasis. 24 The present study also demonstrated that the degree of LIMK1 expression was determined by whether cells were from normal ovarian tissue, benign or borderline ovarian tumours, or primary ovarian carcinoma.
The relationship between expression of LIMK1 and degree of tumour differentiation in ovarian carcinoma samples showed that LIMK1 protein levels increased with increasingly poor tumour differentiation ( Table 1 ). In addition, other research has found that LIMK1 expression was necessary for cell invasion and division. 18 It is possible, therefore, that activation of LIMK1 promotes proliferation and invasion of cancer cells, leading to ovarian cancer development.
The present study has indicated that increased LIMK1 expression may be associated with ovarian cancer progression, and suggests the possibility that inhibition of LIMK1 activity in cancer cells may be sufficient to inhibit tumour cell invasiveness significantly. The present study provides an experimental foundation for examining whether therapeutic strategies, based on RNA interference technology or other relevant methods, might be used to reduce LIMK1 activity and so inhibit ovarian cancer cell invasion.
